FDA labels Ecstasy a breakthrough treatment For PTSD
The U.S. Food and Drug Administration (FDA) has designated 3,4-methylenedioxymethamphetamine, known as ecstasy, a breakthrough therapy for the treatment post-traumatic stress disorder (PTSD). Eight million people suffer from PTSD annually. Thanks to this designation, the drug could have a faster path to pharmaceutical approval. RELATED ARTICLE: DEA approves a study using Ecstasy to treat PTSD The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the FDA’s ruling last week. Now, they can move forward on two of their upcoming “Phase 3” trials. The trials will include 200 to 300 participants, accepting its first test subjects in 2018. “For the first time, psychedelic-assisted psychotherapy will...
Read More